Wedbush Starts Climb Bio (CLYM) at Outperform

Wedbush analyst Laura Chico initiates coverage on Climb Bio (NASDAQ: CLYM) with a Outperform rating and a price target of $12.00.

The analyst comments "We are initiating coverage of Climb Bio (CLYM) with an Outperform rating and $12 target. In biotech, being first doesn't always mean being best and we believe budoprutug and CLYM116 carry differentiated profiles versus standard of care. Budoprutug's indication lineup differs versus other anti-CD19's like Uplizna; however, we see good rationale for use in disease settings like pMN. CLYM116 leverages a validated mechanism in IgAN with APRIL and holds potential to improve on both efficacy and dosing interval versus agents like Voyxact. CLYM also holds a full catalyst calendar: preliminary CLYM116 Phase 1 healthy volunteer data arrives ~mid-2026, with additional budoprutug readouts in 2H26. Cash runway into 2028 enables multiple data cards to turn over. We model FY33 revenue reaching $1,038M (budoprutug in pMN/ITP; CLYM116 in IgAN) with our base case target at $12/sh. We see downside to ~$3/sh on cash alone, and upside to ~$20/sh on pipeline execution."

For an analyst ratings summary and ratings history on Climb Bio click here. For more ratings news on Climb Bio click here.

Shares of Climb Bio closed at $7.28 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Freedom Broker Starts Carnival Corporation (CCL) at Buy
• JPMorgan Starts Arashi Vision Inc (688775:CH) at Neutral